SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Iijima, Y. Articles by Sato, Y. Search for Related Content PubMed PubMed Citation Articles by Iijima, Y. Articles by Sato, Y. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 6 (March 15), 2000: pp. 2126-2131 NEOPLASIA A new ETV6 / TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation Yoshimi Iijima, Takashi Ito, Tsuneyuki Oikawa, Mariko Eguchi, Minenori Eguchi-Ishimae, Nanao Kamada, Kenji Kishi, Shigetaka Asano, Yoshiyuki Sakaki, and Yuko Sato Division of Molecular Cytogenetics, Department of Clinical Pathology, Research Institute, International Medical Center of Japan, Tokyo, Japan; Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Department of Cell Genetics, Sasaki Institute; Department of Cancer Cytogenetics, Research Institute or Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Fourth Department of Internal Medicine, School of Medicine, Tokai University; Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.     Abstract Top Abstract Introduction Materials and methods Results Discussion References The ETV6/TEL gene has been reported to fuse to PDGFRb MDS1/EVI1, BTL, ACS2, STL, JAK2, ABL, CDX2, TRKC, AML1, and MN1. Among them, PDGFR, ABL, JAK2, and TRKC are tyrosine kinases (TK). We identified a novel ETV6 partner gene, ARG (ABL-related gene or ABL2), another TK gene in a cell line established from a patient with acute myelogenous leukemia (AML-M3) with a t(15;17)(q22;q11.2) and a t(1;12)(q25;p13), which has the remarkable feature to differentiate to mature eosinophils in culture with all-trans retinoic acid and cytokines. The ETV6/ARG transcripts consisted of exon 1 to 5 of ETV6 and the 3' portion of ARG starting from exon 1B or exon 2, resulting in an open reading frame for a fusion protein consisting of the entire PNT oligomerization domain of ETV6 and all of the functional domains of ARG including the TK domain. This is the same protein structure as identified in the other ETV6 TK fusion proteins. The reciprocal ARG/ETV6 transcript was not expressed, and the normal ETV6 allele was not deleted or rearranged. Although the ABL is known to be involved in various human malignancies, ARG has not been involved in human malignancies despite its high homology to ABL. Thus, this is the first report showing involvement of ARG in human leukemia. The ETV6/ARG protein may be involved in the unique differentiation capacity of this cell line. (Blood. 2000;95:2126-2131) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References ETV6 (also known as TEL), initially cloned as a partner gene of platelet-derived growth factor receptor  (PDGFR) in a t(5;12)(q33;p13) translocation, is a member of the ETS family of transcription regulators.1 It contains 2 functional domains, a 5' pointed (PNT) domain and a 3' ETS DNA binding domain,1 and fuses to a number of different partner genes such as MDS1/EVI1(3q26),2 BTL(4q11),3 ACS2(5q31),4 STL(6q23),5 JAK2(9p24),6,7 ABL(9q34),7,8 CDX2(13q12),9 TRKC(15q24),10,11 AML1(21q22),12,13 and MN1(22q11).14 Among them, PDGFR, JAK2, ABL, and TRKC are tyrosine kinase (TK) genes. In the fusion proteins, the PNT domain of ETV6 activates the TK domain of the TK genes,1,7,15 or modifies the properties of the transcription factor as AML1.12 Moreover, it is revealed that not only the functional domains of ETV6/TK proteins but also other sequences may contribute to the properties of the fusion proteins. The same ETV6/TRKC transcript was found in a benign neoplasm (familial fibrosarcoma)10 and in a malignancy (acute myelogenous leukemia [AML]-M2 with an aggressive clinical course).11 Although the 2 putative proteins contained the same functional domains (the PNT domain of ETV6 and the TK domain of TRKC), the sequences were different: ETV6/TRKC protein in familial fibrosarcoma contained an additional 14 amino acids just downstream of the TRKC TDYYR motif,11 whereas the protein in acute leukemia did not contain ETV6 exon 5,11 which may explain the difference. Here, we report the identification of a novel partner of ETV6, ARG (ABL-related gene or ABL2), another TK, in a cell line established from a patient with AML-M3 with a t(1;12)(q25;p13) and a t(15;17)(q22;q11.2). This translocation resulted in the fusion of the PNT domain of ETV6 to all of the functional domains of ARG. Although ABL is known to be involved in various human malignancies and ARG shows high homology to ABL, ARG is not yet reported to be involved in human malignancies. This is the first report that shows ARG involvement in human leukemia.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cell lines The patient was a 66-year-old man with AML-M3. He was successfully induced to the first and second remission with combined chemotherapy. At the second relapse, he was referred to the Niigata University Hospital to be treated with all-trans retinoic acid (ATRA). However, he returned to the previous hospital without receiving ATRA therapy due to his family circumstance. The HT93A cell line was established by one of us (K.K.) from peripheral blood mononuclear cells obtained at the second relapse.At the second relapse, the patient's blood cells showed the following karyotype: 46, XY,1q, inv(3),4q,6q+,11p+q,12p+,15q+,17q, 21q+,22q+. When the cell line was established, the karyotype was 46, XY, t(1;12)(q25;p13),2q+, t(4;6)(q12;q13), t(15;17)(q22;q11). Further cytogenetic studies revealed that an additional part of 2q+ was derived from the long arm of chromosome 1, that is, the der(2)t(1;2)(q25;q33). We also determined the breakpoint of t(15;17) more precisely as t(15;17)(q22;q11.1). Thus, the corrected karyotype was 46, XY, t(1;12)(q25;p13), der(2)1(1;2)(q25;q33), t(4;6)(q12;q13), t(15;17)(q22;q11.1). With reverse transcriptase-polymerase chain reaction (RT-PCR) using the primers described elsewhere,16 a short type PML-RARA transcript was detected. The characteristics of the HT93A cell line are described elsewhere.17 In brief, this cell line has the remarkable capacity to differentiate into eosinophils in culture with ATRA and granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) or interleukin-5 (IL-5), although in culture with ATRA alone, the cells differentiate predominantly into neutrophils. HL60 and K562 were used as controls. Fluorescent in situ hybridization For fluorescent in situ hybridization (FISH) probes, we used the YAC964c10 (kindly provided by Dr Janet D. Rowley, Section of Hematology/Oncology, the University of Chicago, Chicago, IL), which contains the entire ETV6 gene, and the LL12NCO1 cosmid probes (kindly provided by Dr Peter Marynem, University of Leuven, Leuven, Belgium) located within the ETV6 in the following order: 5'-179A6-50F4-2G8-163E7-184C4-148B6-3' (Figure 1A). The probes were labeled with biotin-11-dUTP (Boehringer Mannheim, Mannheim, Germany) using nick translation and were hybridized to the HT93A metaphase cells. The probes were detected with Cy-3-Avidin (Amersham Pharmacia, Upsala, Sweden), and then counterstained with 4', 6-diamindino-2-phenylindole dihydrochloride (DAPI). The presence or absence of the FISH signals was scored on an average of 18 cells (range, 15-21) per probe. Images of the hybridized signals and the DAPI were captured with a liquid-cooled, charge-coupled device camera (Quantix: Photometrics, Tucson, Ariz). View larger version (25K): [in this window] [in a new window]   Fig 1. FISH analysis and Southern and Northern hybridizations. (A) Physical map surrounding ETV6 and the location of the cosmid and YAC probes used in FISH analysis. (B) Schematic representation of ETV6 and the probes used for Southern and Northern hybridizations. Southern blot analysis High-molecular weight DNA for Southern hybridization was extracted from each cell line by the standard procedure.18 DNA (10 µg) was digested to completion either with Bam HI, Eco RI, or Sac I and size-fractionated on a 0.7% agarose gel. The DNA was transferred to Hybond-N nylon membrane (Amersham Pharmacia). Probes used for hybridization were full length ETV6 complementary DNA (cDNA; kindly provided by Dr Todd Golub, Division of Hematology/Oncology, Brigham and Women's Hospital, University of Harvard, Boston, Mass), ETV6 cDNA fragment of exons 1 to 5 (A-I probe: nt 1-1039), and ETV6 cDNA fragment of exons 6 to 8 (A-II probe: nt 1040-1580). A-I and A-II probes were obtained by digestion of full length ETV6 cDNA by Acc I (Figure 1B). The probes were labeled with 32P-dCTP by random priming and used for hybridization. Hybridization was performed in 0.5 mol/L NaH2PO4/Na2HPO4, pH7.2, 7% sodium dodecyl sulfate (SDS), 1 mmol/L EDTA, with radiolabeled ETV6 probes at 65°C. Washes were performed in 40 mmol/L NaH2PO4/Na2HPO4, 1% SDS at 65°C. Northern blot analysis Total RNA was extracted by the acid guanidinium phenol-chloroform method using ISOGEN reagent (Nippon Gene, Toyama, Japan). Total RNA (10 µg) was size-fractionated on a 1% agarose/formaldehyde gel and transferred to Hybond-N membrane (Amersham Pharmacia). Probes used for hybridization were the same 3 probes as used in Southern blot analysis, ETV6 1A, ETV6 1B, and an ARG 3' probe (nt 3001-3753). The latter 3 probes were prepared from total RNA of the HT93A cells by RT-PCR using the following primers: E1AF (ETV6 exon 1A nt 25-44: 5'-ATGTCTGAGACTCCTGCTCA-3') and E2R (ETV6 exon 2 nt 186-167: 5'-CAGGTGCGCAGGCAGGC GGA-3') for ETV6 1A probe, E1BF (ETV6 exon 1B nt 328-347: 5'-TGTGTCACAGCAGTCTGCCC-3') and E2R for ETV6 1B probe, and A3001F (ARG nt 3001-3020: 5'-GTCCTTATCTCACCCACTCT-3') and A3753R (ARG nt 3753-3734: 5'-CTACCTCTGCACCACATCAC-3') for the ARG 3' probe. Hybridization was performed as described above. The same filter was rehybridized with -actin-specific probe to check the amount of RNA loaded in each lane. 3'-RACE Total RNA was isolated from each cell line using the ISOGEN reagent. The first strand cDNA was synthesized from 2.5 µg of total RNA using the Super Script Pre-amplification System (Gibco-BRL, Gaithersburg, Md) according to the standard procedures with the primer BamTX (5'-CCCGGATCCT15(A/C/G)-3'). The first PCR was performed with primers E4F (ETV6 exon 4 nt 353-372: 5'-GTGATGTGCTCTATGAACTC-3') and BamTX using the first strand cDNA as the template. Diluted product of the first PCR was used for the second, semi-nested PCR with primers E5F (ETV6 exon 5 nt 510-529: 5'-CAGGCCATCCGTGGATAATG-3') and BamTX. The thermal cycling profile was as follows: 94°C for 3 minutes, followed by 30 cycles of 94°C for 30 seconds, 55°C for 1 minute, 72°C for 2 minutes, and a final extension at 72°C for 10 minutes. Products were analyzed on an agarose gel, cloned using the pT7 Blue-Vector (Novagen, Madison, Wis) and subjected to DNA sequencing. RT-PCR Two micrograms of total RNA isolated from each cell line were subjected to cDNA synthesis using the Super Script II-Reverse Transcriptase (Gibco-BRL). Primers E5F and A590R (ARG nt 590-571: 5'-GTGATGCTGAGTGTGTTATC-3') were used to confirm the ETV6/ARG transcripts. Primers E1AF and E1BF in combination with A3753R were used to confirm the full-length ETV6/ARG transcripts. To detect the reciprocal ARG/ETV6 transcripts, primers A11F (ARG nt 11-30: 5'-TCTGTGAGTCGCCTGGAGGC-3') and A211F (ARG nt 211-230: 5'-CAGCAGGTGGGCCGCGTCGG-3') in combination with E7R (ETV6 exon 7 nt 1277-1258: 5'-CTGAACAAAAGCCTTTGTCC-3') and E8R (ETV6 exon 8 nt 1383-1364: 5'-TCAGCATTCATCTTCTTGGT-3') were used. The thermal cycling parameters were described above. Amplified products were electrophoresed on a 1.5% agarose gel and stained with ethidium bromide. DNA sequencing and homology search Cycle sequencing was performed using fluorescein-labeled primers derived from the pT7 Blue-vector (T7: 5'-CTAATACGACTC ACTATAGGG-3' and U19: 5'-GTTTTCCCAGTCACGACGT-3') and the Vistra systems premixed cycle sequencing kit (Amersham Pharmacia). The reaction products were separated on an automated laser fluorescence sequencer (Amersham Pharmacia). DNA sequences were compared to entries of GenBank using the NCBI Blast server.     Results Top Abstract Introduction Materials and methods Results Discussion References FISH study The FISH study indicated that the breakpoint of t(1;12) was located between exon 5 and exon 8 of ETV6. FISH analysis using the YAC964c10 probe showed split signals between the der(1) and the der(12), suggesting the involvement of ETV6 in this t(1;12) translocation.19 Further FISH studies using ETV6 cosmid probes showed definite involvement of ETV6. The signals from the cosmids containing exons 1 to 5 (179A6, 50F4, 2G8, 163E7, and 184C4) were found on the der(1) (Figure 2A), whereas the signals from the cosmid containing exon 8 (148B6) were found on the der(12) (Figure 2B). These results indicated that the 12p13 breakpoint was located between exon 5 and exon 8 of ETV6. The signals on the normal 12p were always observed with YAC probe and every ETV6 cosmid probe, suggesting that the non-translocated allele of ETV6 was intact. View larger version (77K): [in this window] [in a new window]   Fig 2. FISH analysis of the HT93A cells. (A) The signals were found on the der(1) and on the normal 12p with 184C4 probe, which hybridizes to ETV6 exons 3-5. (B) The signals were found on the der(12) and on the normal 12p with 148B6 probe, which hybridizes to ETV6 exon 8. Southern blot hybridization From an additional band detected in each restriction enzyme digest and the restriction map, the breakpoint was speculated between intron 5 and exon 6 of ETV6. Southern blot hybridization using the full length ETV6 cDNA detected a novel band in genomic DNA from the HT93A cells digested with BamHI, EcoRI, and SacI, but not in the DNA from the control cells. The novel band found in the BamHI digest was detected with the A-I probe containing exons 1 to 5 of ETV6, and those found in EcoRI and SacI digests were detected by the A-II probe containing exons 6 to 8 of ETV6 (Figure 3A). From the restriction map of ETV6, the breakpoint of ETV6 was speculated to be located within a 1790 bp region between intron 5 and exon 6 of ETV6 (Figure 3B). View larger version (79K): [in this window] [in a new window]   Fig 3. Genomic Southern hybridization with the ETV6 probes. (A) With the full length ETV6 cDNA probe, additional bands were found only in the HT93A cells, but not in control cells. The additional bands on Bam HI, EcoRI, and SacI digests were hybridized with A-I probe and A-II probe, respectively. (B) Schematic representation of genomic breakpoint in the HT93A cells. Taking into account the restriction map of ETV6, the breakpoint is deduced to localize in a 1780 bp region that encompasses intron 5 and exon 6 of ETV6. Northern blot hybridization An abnormal transcript band detected in Northern blot hybridization contained exons 1 to 5 of ETV6 and a novel fusion sequence. Northern blot hybridization, using the full length ETV6 cDNA probe, detected an abnormal transcript of more than 10 kb only in the HT93A, which was hybridized with the A-I probe but not with the A-II probe (Figure 4A). This suggested that the abnormal transcript contained exons 1 to 5 of ETV6 and an additional sequence encoded by the unknown fusion partner gene. Normal ETV6 transcripts of 2 to 6 kb were also detected in the HT93 A and control cells. View larger version (63K): [in this window] [in a new window]   Fig 4. Northern hybridization. (A) The first hybridization. With full length ETV6 cDNA probe, 6.2 kb transcript (small arrow) was detected in the HT93A, HL60, and K562 cells, but an additional longer transcript (large arrow) was detected only in the HT93A cells. This abnormal transcript was hybridized with A-I (ETV6 exons 1-5) probe but not with A-II (ETV6 exons 6-8) probe. (B) The second hybridization. With the ARG 3' probe, an abnormal transcript (black arrow) was detected only in the HT93A cells at the same position as the abnormal ETV6 transcript in the first hybridization. The 12.5 kb normal transcript of ARG (white arrow) was also detected in HT93A cells and control cells. This abnormal band was hybridized only with ETV6 exon 1A probe. 3'-RACE 3'-RACE and the BLAST search identified that the novel sequence was ARG. To identify the unknown fusion partner of ETV6, 3'-RACE was performed using primers located in exon 4 and exon 5 of ETV6. Sequence analysis of amplification products detected a novel sequence fused to ETV6. BLAST database searching revealed that the novel sequence was identical to ARG, which maps to 1q25. Further sequence analysis revealed 2 types of ETV6/ARG transcripts, 1 containing exon 5 of ETV6 (up to nt 1033) fused to ARG at nt 362 and the other containing exon 5 of ETV6 fused ARG at nt 425 (Figure 5A). The sequence of ETV6 exon 5 was fused in-frame to the ARG sequence up to nt 599, and then followed by an Alu repeat sequence, which provided the priming site for the BamTX primer. Careful examination suggested that the Alu sequence was derived from an intron of ARG, suggesting that these 3'-RACE products were amplified from unspliced ARG transcripts. The ARG sequence from nt 362 or 425 to nt 599 is not known to encode any functional domains. View larger version (40K): [in this window] [in a new window]   Fig 5. Schematic representation of the ETV6/ARG fusion transcripts. (A) The nucleotides and deduced amino acid sequence of the ETV6/ARG fusion transcripts. Two fusion breakpoints of the ARG were detected, at nt 362 and nt 425. Both fusions contain the ETV6 up to nt 1033, and are in-framed. (B) ETV6 has alternative exon 1A and 1B. Four kinds of the ETV6/ARG transcripts were found. The 1A form ETV6 encodes a complete PNT domain, whereas the 1B form ETV6 encodes a truncated PNT domain, because the translation starts at ATG in exon 3. RT-PCR Use of RT-PCR detected 4 types of ETV6/ARG transcripts, which contained exons 1 to 5 of ETV6 and the sequence from exon 1B or exon 2 to the end of ARG. To determine whether or not the ETV6/ARG transcripts contain the sequences coding functional domains of ARG, we performed RT-PCR with primers in ETV6 exon 1A and in the end of ARG, demonstrating 4 kb full length ETV6/ARG transcripts in the HT93A cells. We confirmed that these transcripts contained the sequence from exon 1B or exon 2 to the end of ARG, which encode the Src homology 3 (SH3) domain, SH2 domain, the TK domain of ARG. As for ETV6 sequence, we detected 2 types of amino termini of transcripts, 1 containing exon 1A (ETV6 1A form) and the other containing exon 1B (ETV6 1B form). Because exon 1B of ETV6 has no in-frame ATG start codon in a 233 bp sequence, translation starts at in-frame ATG start codon (nt 289-291) in exon 3, resulting in formation of a shortened protein with a truncated PNT domain. To confirm the breakpoint of ETV6 and ARG, we repeated the RT-PCR with E5F as sense primer and A590R as antisense primer using 4kb ETV6/ARG transcript as the template, and detected 2 types of ARG breakpoint, nt 362 and nt 425. Thus, in the HT93A, 4 types of ETV6/ARG transcripts were detected, ETV6 1A/long ARG (nt 362~), ETV6 1A/short ARG (nt 425~), ETV6 1B/long ARG (nt 362~), and ETV6 1B/short ARG (nt 425~) (Figure 5B). Besides the abnormal ETV6/ARG transcripts, 2 forms of normal ETV6 transcripts, the 1A form and 1B form were also detected. The reciprocal ARG/ETV6 transcript was not detected by RT-PCR, suggesting absence or very low level expression of this transcript. Second Northern blot analysis The abnormal transcript detected in previous Northern blot analysis contained 1A form ETV6 and ARG sequence. In previous Northern blot analysis, we could detect an abnormal transcript band with full length ETV6 cDNA probe and confirmed that this band was hybridized with A-I (ETV6 exons 1-5) probe. To determine whether this abnormal transcript contains ARG sequence and which isoform of ETV6 is expressed, we did the second Northern blot analysis using the ARG 3' probe, the ETV6 1A probe, and the ETV6 1B probe. With the ARG 3' probe, an approximately 10 kb abnormal transcript band was detected only in the HT93A cells at the same position as the abnormal ETV6 transcript in the previous hybridization. In the control cells and HT93A cells, the 12.5 kb normal ARG transcript was also detected. Both normal and abnormal transcript of ARG were overexpressed in HT93A cells compared to the control cell lines. Furthermore, the abnormal ARG band was hybridized with ETV6 1A probe but not with the ETV6 1B probe (Figure 4B). Thus, the abnormal 10 kb transcript contained both ARG sequence and 1A form ETV6 sequence.     Discussion Top Abstract Introduction Materials and methods Results Discussion References ARG was first identified as a closely related gene to ABL through hybridization with v-ABL probes to human placenta DNA.20 The 2 proteins are structurally quite similar, containing the SH3-SH2 domains, TK domain, and the extensive carboxyl-terminal domain (CTD).21 However, several lines of evidence show that 2 proteins are functionally different. ABL is known to fuse to other genes forming chimeric oncogenes, such as Gag/ABL in murine pre-B lymphoma and BCR/ABL in human acute leukemia and chronic myelogenous leukemia. Recently, ABL was also found to fuse to EVT6.8,15 However, ARG has not fused to any other genes nor been involved in human neoplasms so far. Thus, this is the first report showing ARG involvement in a human leukemia through formation of a fusion gene. The ABL oncoproteins, BCR/ABL and EVT6/ABL, have been demonstrated to transform growth factor-dependent hematopoietic cell lines to factor-independent ones or to transform Rat-1 cells.8,22 This property is dependent on the presence of the PNT domain of ETV6 as well as the active TK domain of ABL.8 Recent studies have shown that oligomerization by the coiled-coil motif of BCR or by the PNT domain of ETV6 is essential for constitutive activation of the TK function of the BCR/ABL and EVT6/ABL oncoproteins.8,23 In the other ETV6/TK proteins (ETV6/PDGFRß and ETV6/JAK2), oligomerization by the PNT domain of ETV6 has been also demonstrated to lead to constitutive activation of the TKs.6,24 Considering the high structural similarity between ABL and ARG proteins, it is conceivable that this ETV6/ARG protein has transforming activity through the same molecular mechanism shown for the ETV6/ABL protein and other ETV6/TK proteins. However, it should be noted that several functional differences between ABL and ARG protein have been reported. There is a phosphotyrosine-independent interaction between the BCR and the ABL SH2 domain.25 The ARG SH2 domain, however, exhibited 10-fold weaker affinity for BCR than the ABL SH2 domain.25 In another study to determine whether ARG shares the potential oncogenic properties of ABL, Gag/ARG protein unlike Gag/ABL protein showed no transforming activity in the NIH 3T3 focus formation assay, and the transforming activity was recovered by replacement of the CTD of ARG with that of ABL.26 The further study using engineered Gag/ARG/ABL chimeric molecules revealed that the third SH3 domain-binding site in the CTD of ARG had a suppressive effect on NIH 3T3 transformation.26 We have carefully checked the sequence of ARG in the ETV6/ARG transcripts, especially the sequence of the CTD, but have not found any mutation or deletion. The transforming properties of the ETV6/ARG protein should be examined carefully. Because the PML/RARA transcript was detected in this patient and this cell line and the leukemic cells showed typical morphology of AML-M3, it is likely that PML/RARA protein played a major role and the ETV6/ARG protein played a secondary role in this leukemia. However, the HT93A cells showed the remarkable feature of differentiating into mature eosinophils in culture with ATRA and cytokines, although we do not know whether the patient's leukemic cells had this capacity. Despite the HL60 cells showing multilineage differentiation to neutrophils, macrophages, eosinophils, and basophils, the true AML-M3 cell line having a t(15;17) shows differentiation only to neutrophils and monocytes/macrophages.27 Surprisingly, other investigators have found the same ETV6/ARG transcript in a mature T-ALL cell line with a t(1;10;12) and observed that their cells differentiated into myeloid cells in culture with IL-3 and GM-CSF (F. Griesinger, personal communication, October 29, 1999). Their ETV6/ARG transcripts had the same breakpoint of ETV6 (at nt 1033) and the same 2 breakpoints of ARG (at nt 362 and nt 425). Among ETV6 fusion proteins reported to date, some are involved in both lymphoid and myeloid leukemias.3,6-8,15 The ETV6/ARG protein may be one of them and be associated with the unique differentiation capacity of this cell line. Now, we are examining whether this protein is found in other leukemias using clinical samples with RT-PCR. Further analysis of ETV6/ARG protein would provide further insight into the role of the ETV6 fusion proteins in cell proliferation and differentiation. Added in proof. While this article was in production, another case with ETV6/ARG fusion and inv(16) was published (Blood. 94:12) as the first report.     Acknowledgments We thank Dr Janet D. Rowley for kindly providing the YAC964c10 probe, Dr Todd Golub for ETV6 cDNA probe, and Dr Peter Marynen for the LL12NCO1 ETV6 cosmid probes.     Footnotes Submitted August 2, 1999; accepted November 18, 1999. Supported in part by a Grant-in-Aid for the Second Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan. Reprints: Yuko Sato, Division of Molecular Cytogenetics, Department of Clinical Pathology, Research Institute, International Medical Center of Japan, Toyama 1-21-1, Shinjuku-ku, Tokyo, 162-0052, Japan; e-mail: ysato{at}ri.imcj.go.jp. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307[Medline] [Order article via Infotrieve]. 2. Peeters P, Wlodarska I, Baens M, et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res. 1997;57:564[Abstract/Free Full Text]. 3. Cools J, Bilhou NC, Wlodarska I, et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11-q12;p13). Blood. 1999;94:1820[Abstract/Free Full Text]. 4. Yagasaki F, Jinnai I, Yoshida S, et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer. 1999;26:192[Medline] [Order article via Infotrieve]. 5. Suto Y, Sato Y, Smith SD, Rowley JD, Bohlander SK. A t(6;12)(q23;p13) results in the fusion of ETV6 to a novel gene, STL, in a B-cell ALL cell line. Genes Chrom Cancer. 1997;18:254[Medline] [Order article via Infotrieve]. 6. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309[Abstract/Free Full Text]. 7. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535[Abstract/Free Full Text]. 8. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996;16:4107[Abstract]. 9. Chase A, Reiter A, Burci L, et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood. 1999;93:1025[Abstract/Free Full Text]. 10. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184[Medline] [Order article via Infotrieve]. 11. Eguchi M, Eguchi-Ishimae M, Tojo A, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999;93:1355[Abstract/Free Full Text]. 12. Romana SP, Mauchauffe M, Le CM, et al. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood. 1995;85:3662[Abstract/Free Full Text]. 13. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995;92:4917[Abstract/Free Full Text]. 14. Buijs A, Sherr S, van Baal S, et al. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11 [published erratum appears in Oncogene 1995;11(4):809]. Oncogene. 1995;10:1511[Medline] [Order article via Infotrieve]. 15. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 1995;55:34[Abstract/Free Full Text]. 16. Biondi A, Rambaldi A, Pandolfi PP, et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood. 1992;80:492[Abstract/Free Full Text]. 17. Kishi K, Toba K, Azegami T, et al. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp Hematol. 1998;26:135[Medline] [Order article via Infotrieve]. 18. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989. 19. Sato Y, Bohlander SK, Kobayashi H, et al. Heterogeneity in the breakpoints in balanced rearrangements involving band 12p13 in hematologic malignancies identified by fluorescence in situ hybridization: TEL (ETV6) is involved in only one half. Blood. 1997;90:4886[Abstract/Free Full Text]. 20. Kruh G, King C, Kraus M, et al. A novel human gene closely related to the abl proto-oncogene. Science. 1986;234:1545[Abstract/Free Full Text]. 21. Kruh GD, Perego R, Miki T, Aaronson SA. The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc Natl Acad Sci U S A. 1990;87:5802[Abstract/Free Full Text]. 22. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312[Abstract/Free Full Text]. 23. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587[Abstract/Free Full Text]. 24. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14,845[Abstract/Free Full Text]. 25. Muller AJ, Pendergast AM, Havlik MH, Puil L, Pawson T, Witte ON. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol Cell Biol. 1992;12:5087[Abstract/Free Full Text]. 26. Mysliwiec T, Perego R, Kruh GD. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain. Oncogene. 1996;12:631[Medline] [Order article via Infotrieve]. 27. Khanna-Gupta A, Kolibaba K, Zibello TA, Berliner N. NB4 cells show bilineage potential and an aberrant pattern of neutrophil secondary granule protein gene expression. Blood. 1994;84:294[Abstract/Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Okuda, N. Harakawa, R. A VanEtten, N. Patel, N. Domae, Y. Sato, and H. Hirai Distinct Transforming and Leukemogenic Activities of Tel-Arg and Tel-Abl Oncogenes in Mice: Possible Negative Role for the Transforming Activity in C-Terminus of Arg Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 2845 - 2845. [Abstract] W. Jin, C. Yun, A. Hobbie, M. J. Martin, P. H.B. Sorensen, and S.-J. Kim Cellular Transformation and Activation of the Phosphoinositide-3-Kinase-Akt Cascade by the ETV6-NTRK3 Chimeric Tyrosine Kinase Requires c-Src Cancer Res., April 1, 2007; 67(7): 3192 - 3200. [Abstract] [Full Text] [PDF] J. P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, C. L. Willman, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia PNAS, February 21, 2006; 103(8): 2794 - 2799. [Abstract] [Full Text] [PDF] C. E. Tognon, C. D. Mackereth, A. M. Somasiri, L. P. McIntosh, and P. H. B. Sorensen Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity Mol. Cell. Biol., June 1, 2004; 24(11): 4636 - 4650. [Abstract] [Full Text] [PDF] M. Sattler, L. R. Quinnan, Y. B. Pride, J. L. Gramlich, S. C. Chu, G. C. Even, S.-K. Kraeft, L. B. Chen, and R. Salgia 2-Methoxyestradiol alters cell motility, migration, and adhesion Blood, July 1, 2003; 102(1): 289 - 296. [Abstract] [Full Text] [PDF] K. Q. Tanis, D. Veach, H. S. Duewel, W. G. Bornmann, and A. J. Koleske Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation Mol. Cell. Biol., June 1, 2003; 23(11): 3884 - 3896. [Abstract] [Full Text] [PDF] J. Cools, N. Mentens, M. D. Odero, P. Peeters, I. Wlodarska, M. Delforge, A. Hagemeijer, and P. Marynen Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13) Blood, March 1, 2002; 99(5): 1776 - 1784. [Abstract] [Full Text] [PDF] F. Yagasaki, D. Wakao, Y. Yokoyama, Y. Uchida, I. Murohashi, H. Kayano, M. Taniwaki, A. Matsuda, and M. Bessho Fusion of ETV6 to Fibroblast Growth Factor Receptor 3 in Peripheral T-Cell Lymphoma with a t(4;12)(p16;p13) Chromosomal Translocation Cancer Res., December 1, 2001; 61(23): 8371 - 8374. [Abstract] [Full Text] [PDF] C. Tognon, M. Garnett, E. Kenward, R. Kay, K. Morrison, and P. H. B. Sorensen The Chimeric Protein Tyrosine Kinase ETV6-NTRK3 Requires both Ras-Erk1/2 and PI3-Kinase-Akt Signaling for Fibroblast Transformation Cancer Res., December 1, 2001; 61(24): 8909 - 8916. [Abstract] [Full Text] [PDF] K. Okuda, E. Weisberg, D. G. Gilliland, and J. D. Griffin ARG tyrosine kinase activity is inhibited by STI571 Blood, April 15, 2001; 97(8): 2440 - 2448. [Abstract] [Full Text] [PDF] C. Cao, X. Ren, S. Kharbanda, A. Koleske, K. V. S. Prasad, and D. Kufe The ARG Tyrosine Kinase Interacts with Siva-1 in the Apoptotic Response to Oxidative Stress J. Biol. Chem., April 6, 2001; 276(15): 11465 - 11468. [Abstract] [Full Text] [PDF] S. R. Chakrabarti, R. Sood, S. Nandi, and G. Nucifora Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies PNAS, November 21, 2000; 97(24): 13281 - 13285. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Iijima, Y. Articles by Sato, Y. Search for Related Content PubMed PubMed Citation Articles by Iijima, Y. Articles by Sato, Y. Related Collections Neoplasia Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020